aTyr Pharma, Inc.

NasdaqCM:ATYR Stock Report

Market Cap: US$313.9m

aTyr Pharma Management

Management criteria checks 4/4

aTyr Pharma's CEO is Sanjay Shukla, appointed in Nov 2017, has a tenure of 7.08 years. total yearly compensation is $1.30M, comprised of 43.2% salary and 56.8% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $510.69K. The average tenure of the management team and the board of directors is 6 years and 15.2 years respectively.

Key information

Sanjay Shukla

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage43.2%
CEO tenure7.1yrs
CEO ownership0.2%
Management average tenure6yrs
Board average tenure15.2yrs

Recent management updates

Recent updates

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 09

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Jul 13
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

CEO Compensation Analysis

How has Sanjay Shukla's remuneration changed compared to aTyr Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$1mUS$561k

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$1mUS$450k

-US$35m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$45m

Dec 31 2017US$2mUS$403k

-US$48m

Compensation vs Market: Sanjay's total compensation ($USD1.30M) is below average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Sanjay's compensation has been consistent with company performance over the past year.

CEO

Sanjay Shukla (52 yo)

7.1yrs

Tenure

US$1,300,525

Compensation

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

Leadership Team

NamePositionTenureCompensationOwnership
Sanjay Shukla
President7.1yrsUS$1.30m0.16%
$ 510.7k
Jill Broadfoot
Chief Financial Officer6.4yrsUS$677.84k0.025%
$ 77.9k
Nancy E. Krueger
General Counsel & Corporate Secretary10.2yrsUS$651.28k0.027%
$ 83.3k
Xiang-Lei Yang
Founderno datano datano data
Jayant Aphale
Vice President of Technical Operationsless than a yearno datano data
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno datano datano data
Peter Villiger
Vice President of Corporate Development4.9yrsno datano data
Danielle Campbell
VP of Human Resource3yrsno datano data
Leslie Nangle
Vice President of Researchno datano datano data
Ying Buechler
Executive Director of Biologics Development & Manufacturingno datano datano data
David King
Scientific Consultant6yrsUS$717.31kno data

6.0yrs

Average Tenure

62yo

Average Age

Experienced Management: ATYR's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sanjay Shukla
President7.1yrsUS$1.30m0.16%
$ 510.7k
John Clarke
Independent Director19.3yrsUS$120.84k0.024%
$ 74.0k
Paul Schimmel
Independent Director19.3yrsUS$61.20k1.31%
$ 4.1m
Floyd Bloom
Member of Scientific Advisory Board15.2yrsno datano data
Bruce Beutler
Member of Scientific Advisory Board15.3yrsno datano data
Benjamin Cravatt
Member of Scientific Advisory Boardno datano datano data
Timothy Coughlin
Independent Chairman of the Board7.7yrsUS$92.20k0.067%
$ 209.4k
Osamu Nureki
Member of Scientific Advisory Board15.3yrsno datano data
Susan Ackerman
Member of Scientific Advisory Boardno datano datano data
Wing Wong
Member of Scientific Advisory Boardno datano datano data
Nancy Ip
Member of Scientific Advisory Boardno datano datano data
Jane Gross
Independent Director5.4yrsUS$68.88k0.0072%
$ 22.4k

15.2yrs

Average Tenure

67yo

Average Age

Experienced Board: ATYR's board of directors are seasoned and experienced ( 15.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 16:30
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

aTyr Pharma, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Joseph PantginisH.C. Wainwright & Co.
Roger SongJefferies LLC